Close

SAB Biotherapeutics (SABS) Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/19/2024

1. NFLX
2. ISRG
3. TSM
4. TSLA
5. SPY
6. INFY
7. SNV
8. SMCI
9. NVDA
10. SLB


Go back to SAB Biotherapeutics (SABS) Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus
(NASDAQ: SABS) Delayed: 4.29 -0.17 (3.81%)
Previous Close $4.46    52 Week High $ 
Open $4.31    52 Week Low $ 
Day High $4.31    P/E N/A 
Day Low $4.29    EPS $ 
Volume 891       

(NASDAQ: SABSW) Delayed: 0.03 --0 (-0%)
Previous Close $0.03    52 Week High $ 
Open $0.03    52 Week Low $ 
Day High $0.03    P/E N/A 
Day Low $0.03    EPS $ 
Volume 891